Recepta’s first clinical trial will be a phase II study for ovarian tumor patients with mAb hu3S193 (anti-Lewis Y). The protocol has been already approved by Brazilian IRB’s and also by ANVISA, Brazil’s regulatory agency. Patient enrollment should start in the first semester of 2008. The protocol has already been registered at the National Cancer Institute website and will be filed under the existing IND at the FDA.